NCT00037180终止2 期
Phase II, Randomized, Double-Blind, Multicenter Trial Of Celecoxib Vs Placebo For The Prevention Of Diarrhea Associated With CPT-11/5fu/LV Chemotherapy In Patients With Previously Untreated Metastatic Colorectal Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Pfizer
- 入组人数
- 212
- 试验地点
- 13
- 主要终点
- Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy
研究概览
简要总结
The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as CPT-11, Camptosar), 5-fluorouracil (also known as 5FU), and leucovorin (also known as LV). Preclinical data from animal models suggest that the investigational drug may offer an effective means for preventing CPT-11/5FU/LV-induced diarrhea. It is also hypothesized that the investigational drug-mediated anti-angiogenesis could induce a favorable tumor response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of colorectal cancer (either newly diagnosed or recurrent disease) with evidence of metastatic disease and present or past histological documentation of adenocarcinoma of the colon or rectum.
- •Tumor must be measureable.
- •Resolution of all acute toxic effects of any prior radiotherapy or surgical procedure.
- •ECOG performance status 0 or
- •Age >= 18 years.
- •Required baseline laboratory.
- •Negative pregnancy test.
- •Willingness and ability to comply with the treatment plan.
排除标准
- •Current enrollment in another clinical trial.
- •Prior adjuvant therapy for colorectal cancer <= 6 months prior to randomization.
- •Prior systemic anticancer therapy or intra-arterial cytotoxic chemotherapy given as treatment for metastatic colorectal cancer.
- •Known allergy to CPT-11, 5-FU, LV, celecoxib, other COX-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDS), salicylates, or sulfonamides.
- •Chronic concomitant use of full-dose aspirin, other NSAIDs or other COX-2 inhibitors for a chronic nonmalignant condition.
- •A requirement for chronic concomitant use of low-dose (cardioprotective) aspirin.
- •Chronic oral steroid use for treatment of a non-malignant condition.
- •Known ulceration of the gastric or duodenal mucosa <= 30 days prior to randomization.
- •Need for concomitant fluconazole or lithium.
- •Any known significant bleeding disorder.
- •Active inflammatory bowel disease or chronic diarrhea.
结局指标
主要结局
Incidence of NCI CTC grade 2-4 diarrhea during the first cycle (6 weeks) of CPT-11/5-FU/LV chemotherapy
次要结局
- Duration of diarrhea, by cycle
- Severity of all grades of diarrhea, overall and by cycle
- Diarrhea grade, by day, by cycle
- Stool count, by day, by cycle
- Severity of asthenia (fatigue), by week.
- Asthenia will be assessed with the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scale.
- Duration of asthenia, by week, as measured by the FACIT-Fatigue scale
- Type, frequency, severity, timing, and relatedness of all adverse events CPT-11/5-FU/LV treatment administration as characterized by median, mean, and range of doses given; dose modifications, omissions, and delays; and actual and relative dose intensity
- Compliance with celecoxib use Incidence, quantity, and duration of loperamide use
- Tumor response rate (overall and confirmed)using the World Health Organization [WHO] Response Evaluation Criteria in Solid Tumors [RECIST 2000]
- Serum tumor marker (carcinoembryonic antigen [CEA]) response rate (as characterized by a 50% reduction from baseline)
- Time to tumor progression (TTP)
- Time to treatment failure (TTF)
- Survival Post-study anticancer treatment
- Peak plasma levels and AUC 0-24 values for CPT-11 and its major metabolites, SN-38, SN-38 glucuronide (SN-38G), and aminopentane carboxylic acid (APC)
- Inflammatory cytokines which may serve as biomarkers for cancer-related outcomes Beta-glucuronidase as a potential biomarker for tumor response
- Health resource utilization (collected data to be evaluated separately from this protocol)
研究者
研究点 (13)
Loading locations...
相似试验
终止
2 期
Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19Covid19NCT04860518Faron Pharmaceuticals Ltd7
招募中
2 期
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.Carcinoma, HepatocellularNCT06349980Shanghai Henlius Biotech117
已完成
2 期
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)Diarrhea-predominant Irritable Bowel SyndromeNCT03977155Boston Pharmaceuticals133
已完成
2 期
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell CarcinomasBasal Cell CarcinomaNCT01815840Hoffmann-La Roche229
已完成
2 期
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MMMultiple MyelomaNCT01526694Azienda Ospedaliera di Bolzano30